- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions
European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- Recombinant human interleukin-7 fused to a hybrid crystallis
Pharmaceuticals - Community Register
Community register of orphan medicinal products | GRANTED |
Product information |
Recombinant human interleukin-7 fused to a hybrid crystallisable fragment region of a human antibody
| EU orphan designation number: | EU/3/17/1875
|
| Active ingredient: | Recombinant human interleukin-7 fused to a hybrid crystallisable fragment region of a human antibody |
| Indication: | Treatment of idiopathic CD4 lymphocytopenia |
| Sponsor: | NeoImmuneTech, INC., Spółka Akcyjna, Oddział w Polsce
ul. Dzwonkowa nr 104, 43-100 Tychy, Polska |
Public summary of scientific opinion
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 23/05/2017 | Orphan designation | EMA/OD/321/16 | (2017)3608 of 22/05/2017 |
CONTACT
EU links
Directorate General Health & Consumers